GT BiopharmaGTBP
13F holders, Q1 2025 (March 31)20holders +2
3new positions
1sold out
1famous investor
$2.21avg. 13F price*
At the end of Q1 2025, 20 institutions reported holding GT Biopharma Inc. (GTBP) in their 13F filings, up 2 from Q4 2024. 3 opened new positions and 1 sold out. The largest holders were Geode Capital Management, LLC ($52K), Citadel Advisors ($45K) and Bank of Montreal ($33K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- GT Biopharma Inc.
- CUSIP
- 36254L308
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $45K |
| Exits | 1 | $29.0M |
All 13F filers, Q4 2024 → Q1 2025: 28,420 shares bought and 1,173,612 shares sold, net −1,145,192 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 20 holders
| Geode Capital Management, LLC | 0.00% | Add +55.0% | 23,086 | $52K |
| Citadel Advisors | 0.00% | New | 20,138 | $45K |
| Bank of Montreal | 0.00% | Reduce -49.4% | 14,651 | $33K |
| Vanguard Group Inc. | 0.00% | No change | 10,504 | $24K |
| Wells Fargo & Company | 0.00% | No change | 10,013 | $22K |
| BlackRock, Inc. | 0.00% | No change | 9,737 | $21K |
| Morgan Stanley | 0.00% | No change | 3,533 | $8K |
| Osaic Holdings, Inc. | 0.00% | Add +2.3% | 2,706 | $6K |
| UBS Group AG | 0.00% | Reduce -48.8% | 2,559 | $6K |
| NFSG Corp | 0.00% | No change | 1,750 | $4K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -68.5% | 918 | $2K |
| GHP Investment Advisors, Inc. | 0.00% | New | 33 | $71 |
| Bank of America Corp. | 0.00% | No change | 27 | $59 |
| Blue Bell Private Wealth Management, LLC | 0.00% | No change | 10 | $22 |
| SBI Securities Co., Ltd. | 0.00% | Reduce -50.0% | 8 | $17 |
| Farther Finance Advisors, LLC | 0.00% | No change | 6 | $14 |
| BNP Paribas Financial Markets | 0.00% | No change | 6 | $13 |
| Allworth Financial LP | 0.00% | Reduce -50.0% | 1 | $3 |
| JPMorgan Chase & Co. | 0.00% | No change | 1 | $2 |
| Front Row Advisors LLC | 0.00% | New | 1 | $2 |
"% of holder's portfolio" is GTBP's weight in each manager's 13F, not the share of GT Biopharma Inc. the manager owns.